New name reflects company’s strength and value to clients
Norristown, PA, September 21, 2020 – Myoderm, a leading global clinical trial supply company, announced today that it will begin operating under a new name and will be known as Myonex, effective immediately. The name builds on the reputation that the company has established over the past three decades of service to the global clinical trial industry and also represents the company’s ability to help clients always be prepared for what’s next in their clinical trials.
“This is an ideal time to make this change, because we are focused on providing more complete clinical trial solutions while building upon our roots in exceptional customer service,” said James Lovett, Chief Executive Officer. “Our goal is to make sure our partners have whatever they need when they need it to execute a successful clinical trial, while also minimizing delays, unnecessary costs and surprises.”
The company’s roots date back to 1935, when Morris Cohen purchased an independent pharmacy in Norristown. The company has been under Cohen family ownership for three generations and maintains facilities in North America, United Kingdom, and Denmark.
“As we entered a new decade and our 33rd year in business, we wanted a new name that would capture our evolution as a company,” said Michael Cohen, Executive Chairman and grandson of the company founder. “By keeping ‘myo,” we honor our history and capture the strength of the growing number of services we offer our clients. ‘Nex’ suggests both ‘next’ and ‘nexus’, or central link. We serve as that connection for our clients.”
“When you see the name Myonex, know that it represents the same quality, client focus and expertise for which Myoderm has always been recognized,” said Lovett.
Earlier this summer the company broke ground on a new 65,000-square-foot office and cGMP warehouse in Horsham, Pa. The facility, which is slated for completion in fall 2021 will service as the new U.S. headquarters for Myonex.